Phase II basket study of brigatinib for ALK fusion-positive solid tumors: WJOG15221M/ALLBREAK (a decentralized clinical trial design)
{{output}}
Anaplastic lymphoma kinase (ALK) rearrangements, oncogenic drivers found in 3-5% of non-small cell lung cancer (NSCLC), are also detected in 0.2% of other solid tumors with poor prognosis. Brigatinib, a second-generation ALK-tyrosine kinase inhibitor (ALK-TKI)... ...
